Clinical Trial Update: A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating the safety and efficacy of a WSD0922-FU combination with Osimertinib in non-small cell lung cancer; the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• WSD0922-FU (WSD0922-FU)

Snippet

Sponsor: Wayshine Biopharm, Inc. | Conditions: Non Small Cell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: RECRUITING